Company Profile

Weaker Buy Today AERI ranks #1416 as BUY CANDIDATE. Stronger Buy
Today AERI ranks #1416 as BUY CANDIDATE.

AERI stock Aerie Pharmaceuticals

AERI stock
Aerie Pharmaceuticals

Aerie Pharmaceuticals

2030 Main Street

Irvine, CA 92614



Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, a once-daily eye drop, which has completed Phase III registration trials for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Irvine, California.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank